Drug Discovery

HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19

HiFiBiO Therapeutics has entered into a partnership with South Korea-based ABL Bio to co-develop its SARS-CoV-2 neutralising antibody HFB30132A for the treatment of Covid-19.

Merck to purchase $1bn equity stake in Seattle Genetics

Drug-maker Merck has announced the acquisition of a $1bn equity stake in biotechnology company Seattle Genetics.

Gilead Sciences to acquire ADC developer Immunomedics for $21bn

Gilead Sciences has agreed to acquire Immunomedics, a US biopharma company engaged in the development of antibody-drug conjugates (ADCs) for cancer, in a deal worth around $21bn.

Exelixis, NBE join forces for discovery and development of ADCs for cancer

Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific conjugation and novel payloads.

Cycle Pharmaceuticals secures $25m debt financing

Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, today announced that it has executed a definitive agreement for a $25 million credit facility with Deutsche Bank AG.

Grifols to take full ownership of Alkahest in $146m deal

Spanish healthcare company Grifols has agreed to acquire the remaining stake in Alkahest, a Silicon Valley-based biopharma company, for $146m.

InPro 8000 Series Turbidity Sensor

This fiber optic measuring system is based on the backscattered light principle and consequently provides the highest possible performance from low/medium turbidities right through to high suspended particle concentrations.

Kite, HiFiBiO Therapeutics partner to discover novel targets and antibodies against AML

Kite, a Gilead Company and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML).

Gilead, Jounce Therapeutics sign $805m worth licensing deal for JTX-1811

Gilead Sciences has signed an exclusive licensing deal worth up to $805m with Jounce Therapeutics for the latter's immunotherapy candidate JTX-1811.